Monopar Therapeutics Inc.

NASDAQ:MNPR

$22.53 USD

$1.83 (8.84%)

Volume
70.34K
Average Volume
1.27M
Market Capitalization
$118.91M
P/E Ratio
-0.61
Dividend Yield
0.00%
Price Target
$29.50
Year High
$38.50
Year Low
$1.40
Payout Ratio
$0.00
Current Ratio
$5405.50

Industry, Sector & symbol

Stock Exchange NASDAQ Capital Market
CEO Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Industry Biotechnology
Sector Healthcare
Current Symbol MNPR
CUSIP 61023L108
CIK 0001645469
Web https://www.monopartx.com
Phone 847 388 0349
Currency USD
Employees 9
Country US

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 5405.50
Quick Ratio 5405.50
Cash Ratio 5.36

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow -125.19
Price / Cash Flow -0.03
Price / Book 160.34

Price Target and Rating

Average Stock Price Forecast $29.50
High Stock Price Forecast $37.00
Low Stock Price Forecast $22.00
Forecast Upside/Downside -23.63%
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 3 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.58
Trailing P/E Ratio -0.61
PEG Ratio -0.05
P/E Growth -0.05
Net Income $-8.4M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity -21731.73%
Return on Assets -21573.66%

Financials Score

AltmanZ Score 1244.55
Piotroski Score 1.00
Working Capital 6.07B
Total Assets 6.07M
Ebit -7M
Market Cap 118.91M
Total Liabilities 1.12M

Poll Results

About Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR ... -202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

2024-11-25 19:53:28

Monopar Therapeutics is a clinical-stage biotech focused on radiopharmaceuticals for oncology and recently expanded into rare diseases with ALXN-1840. MNPR's oncology pipeline includes MNPR-101-Zr for diagnostics and MNPR-101-Lu/Ac for therapeutic applications, both in the early development stages. ALXN-1840, a Phase 3 asset for Wilson disease, diversifies MNPR's portfolio but does not directly complement its oncology focus.

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

2024-11-08 08:00:00

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

2024-10-30 13:42:00

WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company.

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

2024-10-28 21:15:00

WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The offering is expected to close on October 30, 2024, subject to satisfaction of customary closing conditions.

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

2024-10-28 16:00:00

WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it intends to offer to sell shares of its common stock in a best efforts public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Frequently Asked Questions

What is the current Monopar Therapeutics Inc. (MNPR) stock price?

Monopar Therapeutics Inc.(NASDAQ:MNPR) stock price is $22.53 in the last trading session. During the trading session, MNPR stock reached the peak price of $38.5 while $1.4 was the lowest point it dropped to. The percentage change in MNPR stock occurred in the recent session was 8.84% while the dollar amount for the price change in MNPR stock was $1.83.

MNPR's industry and sector of operation?

The NASDAQ listed MNPR is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of MNPR?

Mr. Karthik Radhakrishnan CFA | Chief Financial Officer, Principal Accounting Officer & Principal Financial Officer
Dr. Christopher M. Starr Ph.D. | Co-Founder & Independent Executive Chairman of the Board
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | Co-Founder, Chief Executive Officer, President & Director
Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer
Mr. Andrew J. Cittadine M.B.A. | Chief Operating Officer

How many employees does MNPR have?

Number of MNPR employees currently stands at 9. MNPR operates from 1000 Skokie Boulevard, Wilmette, IL 60091, US.

Link for MNPR official website?

Official Website of MNPR is: https://www.monopartx.com

How do I contact MNPR?

MNPR could be contacted at phone #847 388 0349 and can also be accessed through its website. MNPR operates from 1000 Skokie Boulevard, Wilmette, IL 60091, US.

How many shares of MNPR are traded daily?

The average number of MNPR shares traded daily for last 3 months was 1.27M.

What is the market cap of MNPR currently?

The market value of MNPR currently stands at $118.91M with its latest stock price at $22.53